Evidence map›Paper›PMID 35070423›Full record

ArticleJournal of gastrointestinal oncology2021

High expression of Ran binding protein 1 predicts poor outcomes in hepatocellular carcinoma patients: a Cancer Genome Atlas database analysis.

Zhengxiao Wei, Xiaoqiong Duan, Qi Li, Qingfeng Li, Yu Wang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Ran GTPase and Its Importance in Cellular Signaling and Malignant Phenotype.International journal of molecular sciences · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Zhengxiao WeiDepartment of Clinical Laboratory, Public Health Clinical Center of Chengdu, Chengdu, China.
Xiaoqiong DuanInstitute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China.
Qi LiCollege of Bioinformatics, Chongqing University of Posts and Telecommunications, Chongqing Key Laboratory of Big Data for Bio-intelligence, Chongqing, China.
Qingfeng LiDepartment of Clinical Laboratory, Public Health Clinical Center of Chengdu, Chengdu, China.
Yu WangCollege of Bioinformatics, Chongqing University of Posts and Telecommunications, Chongqing Key Laboratory of Big Data for Bio-intelligence, Chongqing, China.
Chongqing University of Posts and Telecommunications · CNPublic Health Clinical Center of Chengdu · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRan-specific binding protein 1 (RANBP1) is involved in the regulation of the cell cycle, while its role in hepatocellular carcinoma (HCC) is unknown. Therefore, we aimed to demonstrate the association of RANBP1 with clinicopathologic features and potential biological functions in HCC based on The Cancer Genome Atlas (TCGA) data.

methodsWe assessed

resultsThe expression of

conclusionsFindings suggest that

Indexed as

Hepatocellular carcinoma (HCC)immune infiltrationprognosisRan-specific binding protein 1 (RANBP1)The Cancer Genome Atlas database (TCGA database)

Identifiers

PMID35070423
PMCPMC8748041
OpenAlexW3213998207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.